Table 1.
Demographics, clinical characteristics and treatment of patients recovered from COVID-19 with positive results of SARS-CoV-2
| Patients (n = 61) | |
|---|---|
| Age, years | 54.79 (12.89) |
| ≤ 29 | 3 (4.9%) |
| 30–39 | 7 (11.5%) |
| 40–49 | 12 (19.7%) |
| 50–59 | 18 (29.5%) |
| 60–69 | 15 (24.6%) |
| 70–79 | 6 (9.8%) |
| Sex | |
| Female | 36 (59%) |
| Male | 25 (41%) |
| Chronic medical illness | 24 (39.3%) |
| Chronic obstructive pulmonary disease | 8 (13.1%) |
| Hypertension | 5 (8.2%) |
| Diabetes | 5 (8.2%) |
| Digestive system disease | 2 (3.3%) |
| Cerebrovascular disease | 1 (1.6%) |
| Chronic kidney disease | 1 (1.6%) |
| Chronic hepatitis | 2 (3.3%) |
| Symptoms after discharge from hospital | |
| Fever | 15 (24.6%) |
| Sore throat | 8 (13.1%) |
| Cough | 11 (18%) |
| Shortness of breath | 3 (4.9%) |
| Sputum production | 9 (14.8%) |
| Headache | 5 (8.2%) |
| Fatigue | 3 (4.9%) |
| Diarrhoea | 3 (4.9%) |
| Asymptom | 38 (62.3%) |
| Positive results | |
| Nasal and pharyngeal swab | 36 (59%) |
| Stool | 17 (27.9%) |
| Sputum | 8 (13.1%) |
| Disease severity status | |
| Mild | 38 (62.3%) |
| General | 20 (32.8%) |
| Severe | 3 (4.9%) |
| Critical | 0 |
| Laboratory findings | |
| Leucocyte count (× 109 per L; normal range 3.5–9.5) | 6.9 (4.5–8.5) |
| > 9.5 | 8 (13.1%) |
| < 3.5 | 11 (18%) |
| Neutrophil count (× 109 per L; normal range 1.8–6.3) | 4.9 (3.4–5.9) |
| > 6.3 | 14 (22.9%) |
| Lymphocyte count (× 109 per L; normal range 1.1–3.2) | 1.5 (0.8–1.9) |
| < 0·8 | 17 (27.9%) |
| Platelets count (× 109 per L; normal range 100–300) | 155 (128–175) |
| < 100 | 4 (6.6%) |
| Procalcitonin, ng/mL (normal range < 0.05) | |
| ≥ 0.05, n (%) | 6 (9.8%) |
| C-reactive protein (mg/L; normal range 0–5) | 3.2 (1.7–28.6) |
| ≥ 5.0 | 19 (31.1%) |
| D-dimer (mg/L; normal range 0–500) | 164 (65–327) |
| > 500 | 7 (11.5%) |
| Albumin (g/L; normal range 40–55) | 33.7 (28.4–37.6) |
| < 40 | 58 (95.1%) |
| Alanine aminotransferase (U/L; normal range 9–50) | 27 (19–36) |
| > 50 | 5 (8.2%) |
| Aspartate aminotransferase (U/L; normal range15–40) | 24 (15–33) |
| > 40 | 4 (6.6%) |
| Blood urea nitrogen (mmol/L; normal range3.6–9.5) | 6.1 (4.7–7.3) |
| > 9.5 | 5 (8.2%) |
| Serum creatinine (μmol/L; normal range 57–111) | 80 (67–95) |
| > 111 | 9 (14.8%) |
| Lactate dehydrogenase (U/L; normal range 120–250) | 172 (150–262) |
| > 250 | 14 (22.9%) |
| Radiologic findings | |
| Abnormalities on chest radiograph | 23 (37.7%) |
| Ground-glass opacity | 3 (4.9%) |
| Local patchy shadowing | 9 (14.8%) |
| Bilateral patchy shadowing | 8 (13.1%) |
| Interstitial abnormalities | 3 (4.9%) |
| Normalities on chest radiograph | 38 (62.3%) |
| Length of stay in hospital, days | 18.0 (14.0–22.5) |
| Length of positive result for COVID-19 after hospital discharge, days | 10 (7–13) |
| < 14 | 47 (77%) |
| 14–28 | 9 (14.8%) |
| > 28 | 5 (8.2%) |
| Treatment | |
| Oxygen therapy | 21 (34.4%) |
| Non-invasive mechanical ventilation | 2 (3.3%) |
| Antiviral treatment | 23 (37.7%) |
| Antibiotic treatment | 20 (32.8%) |
| Glucocorticoids | 2 (3.3%) |
| Convalescent plasma therapy | 3 (4.9%) |
| Clinical outcomes at data cutoff | |
| Hospitalization | 22 (36.1%) |
| Hospital Discharge | 1 (1.6%) |
| Centralized isolation for medical observation | 38 (62.3%) |
Data are n (%), mean (SD) and median (IQR).OVID-19: coronavirus disease 2019, SARS-CoV-2: severe acute respiratory syndrome coronavirus 2